Avalo Therapeutics AVTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.32M+57.2% | $16.11M-40.9% | $27.26M-35.9% | $42.52M-66.0% | $125.24M-7.0% | ||
| $57.01M— | —— | —— | —— | —— | ||
| $88.83M-15.6% | $105.29M-7.5% | $113.85M-1.2% | $115.19M-9.3% | $126.94M-8.6% | ||
| $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | $10.5M0.0% | ||
| $99.89M-14.2% | $116.46M-6.9% | $125.1M-1.2% | $126.58M-8.6% | $138.52M-8.1% | ||
| $356K+160% | $137K-71.1% | $474K-80.0% | $2.37M+247% | $681K+141% | ||
| $11.6M-10.4% | $12.94M+62.3% | $7.97M-13.9% | $9.26M+64.9% | $5.62M-19.3% | ||
| $31.57M-5.5% | $33.41M-0.4% | $33.55M+52.5% | $22.01M+38.4% | $15.91M-10.1% | ||
| 200M0.0% | 200M0.0% | 200M0.0% | 200M0.0% | 200M+1,999,900% | ||
| -$468.15M-4.4% | -$448.52M-3.2% | -$434.8M-7.6% | -$404.18M-5.4% | -$383.41M-3.6% | ||
| $68.32M-17.7% | $83.05M-9.3% | $91.55M-12.5% | $104.57M-14.7% | $122.62M-7.8% | ||
| $99.89M-14.2% | $116.46M-6.9% | $125.1M-1.2% | $126.58M-8.6% | $138.52M-8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's total assets?
- Avalo Therapeutics (AVTX) holds $99.9M in total assets, down 27.9% year over year.
- How much debt does Avalo Therapeutics have?
- Avalo Therapeutics carries $328.0K in total debt against $68.3M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Avalo Therapeutics have?
- Avalo Therapeutics holds $25.3M in cash and equivalents.
- Can Avalo Therapeutics cover its short-term obligations?
- Its current ratio is 7.66 — current assets exceed current liabilities.
- Where does Avalo Therapeutics's balance sheet data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
